Dr. Paul Higham
Chief Scientific Officer
Paul Higham, PhD leads scientific affairs for AgNovos Bioscience. In that role, Dr. Higham assesses the fundamental science underpinning the company’s technology platforms and current and future product portfolio. Additionally, Dr. Higham partners with global marketing, R&D, and business development to shape the Company’s long-term growth and innovation strategy. Prior to joining AgNovos, Dr. Higham managed his own consulting company which focused on strategic projects for start-up medical technology companies. In that capacity, he led the development of a novel drug-eluting technology for osteoarthritis as well as a novel hydrogel neurosurgical hemostat technology. Dr. Higham has over thirty years of experience in R&D, product development, and business development at Pfizer and Stryker. He holds 29 patents and currently serves on a number of advisory boards, including those of Nasseo, Inc and TaraGenyx, and has a position on the Board of Directors for Avitus Orthopaedics and Fusion Implants. Dr. Higham received his bachelors degree from Manchester Polytechnic (UK) and his PhD from University of Manchester (UK).